Form 4: Evolent Health: Executive Receives Restricted Stock Units

Evolent Health, Inc. reports that Chief Accounting Officer Shams Aammaad was granted 28,790 restricted stock units under the company's 2015 Omnibus Incentive Compensation Plan.

Summary

• Shams Aammaad, Chief Accounting Officer at Evolent Health, Inc., received a grant of 28,790 restricted stock units (RSUs) on July 1, 2026.
• These RSUs were granted under the company's Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• The grant follows shareholder approval on June 4, 2026, for additional shares under the incentive plan.
• The securities vest over three years: 34% on July 1, 2027, and 33% on July 1, 2028, and July 1, 2029.
• Following this transaction, Mr. Aammaad beneficially owns 95,637 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine executive compensation and stock grants rather than significant financial performance or strategic shifts.

Positives

• Grant of restricted stock units to a key executive, indicating continued incentive alignment.
• The grant is part of an annual award cycle and follows shareholder approval for additional shares, suggesting a structured and approved compensation process.
• The vesting schedule over three years promotes long-term retention and commitment from the executive.

Negatives

• The filing details a stock-based compensation award, which can dilute existing shareholder value if not managed effectively.
• No financial performance metrics are associated with this specific grant, making it difficult to assess direct performance linkage.

Risks

• Potential for future dilution of existing shareholder equity due to stock-based compensation awards.
• The value of the RSUs is subject to the future stock price performance of Evolent Health, Inc.

Future Outlook

The filing indicates a structured approach to executive compensation with RSUs vesting over three years, suggesting a focus on long-term employee retention and alignment with shareholder interests.

Management Comments

• The grant of RSUs is part of the annual award cycle and follows shareholder approval for additional shares under the incentive plan.
• The vesting schedule is designed to incentivize continued service and performance over multiple years.

Industry Context

StockSavvy.ai notes that the issuance of restricted stock units to key executives is a common practice in the healthcare technology sector to attract, retain, and motivate talent, aligning their interests with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: Potential for slight dilution of ownership with the issuance of new shares, but also potential for increased executive motivation and long-term value creation.
• Employees: Reinforces the company's commitment to its incentive compensation plans, potentially motivating other employees.
• Management: Direct benefit to Shams Aammaad through the stock grant.

Next Steps

• Vesting of restricted stock units on July 1, 2027, July 1, 2028, and July 1, 2029.
• Continued monitoring of Evolent Health's stock performance and executive compensation practices.

Key Dates

Keywords

Evolent Health, EVH, Form 4, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Insider Trading, Securities Exchange Act, Omnibus Incentive Compensation Plan, Chief Accounting Officer